Synthetic peptides have proven to be a valuable tool for investigating the binding capacities, proteolytic activities and immunogenicity properties of proteins, enabling the development of vaccine candidates that can create a specific protective immune response by stimulating both cellular and humoral immunity with the B and T cell epitopes.588 Since the 1990s, researchers have been developing vaccines to raise cellular immunity against cancer cells that bear excessive amounts of p53 protein. The gene discussed is TP53; the disease is cancer.